GNI Group Ltd. (JP:2160)
:2160
Want to see JP:2160 full AI Analyst Report?
2160 Stock Chart & Stats
¥3370.00
¥50.00(1.64%)
At close: 4:00 PM EST
¥3370.00
¥50.00(1.64%)
Day’s Range― - ―
52-Week Range¥2,112.00 - ¥4,220.00
Previous CloseN/A
Volume492.20K
Average Volume (3M)969.16K
Market Cap
¥158.15B
Enterprise Value¥127.25B
Total Cash (Recent Filing)¥19.87B
Total Debt (Recent Filing)¥5.17B
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Aug 17, 2026EPS Estimate
-2.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-112.69
Shares Outstanding55,827,010
10 Day Avg. Volume1,104,200
30 Day Avg. Volume969,156
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,800.00Price Target Upside12.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)53.4
Revenue Forecast (FY)¥29.67B
Bulls Say, Bears Say
Bulls Say
High Revenue Growth & Gross MarginsSustained TTM revenue growth of ~76.5% alongside ~74% gross margins indicates durable product demand and pricing power. High gross margins support reinvestment in R&D and commercialization, enabling long-term scaling of core therapies rather than relying on transient market moves.
Conservative Leverage / Solid CapitalizationVery low debt-to-equity (~0.10) and a sizable equity base provide financial flexibility to fund clinical programs and partnerships without immediate refinancing pressure. This reduces bankruptcy risk and supports multi-period R&D investment typical for biotech businesses.
Robust Pipeline And Licensing ModelA diversified pipeline plus licensing/partnership activities create multiple, structurally different value drivers: product sales, milestone/licensing income, and royalties. Partnerships can share development risk and expand commercialization reach, strengthening long-term growth prospects.
Bears Say
Negative Profitability & Operating LossesNegative net margins and recurring operating losses imply the business is not currently generating sustainable earnings from operations. Over months this elevates reliance on external funding, pressures management to restore profitability, and weakens accrual returns to shareholders if trends persist.
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow increases funding risk and may force dilutive equity or costlier debt raises. For a company with lumpy R&D and commercial outlays, inability to self-fund operations reduces strategic optionality and can delay development milestones or commercial scale-up.
Profitability Volatility And Weaker ReturnsNegative ROE and historical balance sheet volatility indicate execution and earnings inconsistency. Such variability complicates forecasting, raises investor uncertainty, and suggests that strong revenue growth has not reliably converted into durable shareholder returns over recent years.
GNI Group News
2160 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was ¥2112.00 and its highest was ¥4220.00 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is ¥158.15B.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 70 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on May 15, 2026. The company reported -¥38.2 earnings per share for the quarter, missing the consensus estimate of -¥2.74 by -¥35.46.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Undervalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is -2.63.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 55,827,010 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of -¥38.2 in its last earnings report, missing expectations of -¥2.74. Following the earnings report the stock price went down -1.99%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in JP:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.
2160 Stock 12 Month Forecast
Average Price Target
¥3,800.00
▲(12.76% Upside)
Technical Analysis
Peptidream
―
SanBio Co
―
Sosei Group
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
Options Prices
Currently, No data available
---